Brief Title
Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome
Official Title
Ocular Conservative Treatment for Retinoblastoma: Efficacy of the New Management Strategies and Visual Outcome - RETINO 2018
Brief Summary
This protocol includes 2 independent studies. Both studies are multicenter studies,
evaluating different therapeutic approaches in two different populations of patients:
- Study 1, a randomized phase-II study evaluating the efficacy of Intra-Arterial
Chemotherapy (IAC) with melphalan and topotecan versus melphalan alone, both in
association with ophthalmologic treatments.
- Study 2, a minimally invasive interventional study evaluating the results on visual
function following reference treatment with intravenous (IV) chemotherapy in association
with ophthalmologic or local ophthalmological treatment without IV chemotherapy.
Detailed Description
Primary objective of the studies:
- Study 1: To evaluate the efficacy of IAC in term of local control of the disease in
patients eligible for IAC (randomized phase II study);
- Study 2: To assess the visual function, based on World Health Organization (WHO)
criteria, in patients eligible for other conservative treatments (IV chemotherapy in
association with local ophthalmologic trématent or local ophthalmological treatment
without IV chemotherapy; this is a minimally invasive interventional study).
Study Phase
Phase 2/Phase 3
Study Type
Interventional
Primary Outcome
Study 1: Rate of eye preservation
Secondary Outcome
Ocular toxicity
Condition
Retinoblastoma
Intervention
Melphalan or Melphalan + Topotecan
Study Arms / Comparison Groups
Study 1: Melphalan or Melphalan + Topotecan
Description: Randomized phase-II study evaluating the efficacy of Intra-Arterial Chemotherapy (IAC) with melphalan and topotecan versus melphalan alone, both in association with ophthalmologic treatments.
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Drug
Estimated Enrollment
225
Start Date
March 25, 2021
Completion Date
January 20, 2036
Primary Completion Date
January 20, 2035
Eligibility Criteria
Inclusion Criteria:
Overall study inclusion criteria:
1. Newly diagnosed retinoblastoma (RB).
2. Retinoblastoma with at least one eye eligible for conservative management.
3. Patients likely to be compliant with the study requirements and visits, including late
follow-up.
4. Patients not previously treated with chemotherapy or radiotherapy for this or any
other cancer.
5. Patients with no contraindication to the proposed treatments.
6. Informed consent signed by parents or legal representative.
7. French Social Security System coverage.
Study 1 inclusion criteria:
8.1. Children aged from 6 months to 6 years. 9. Retinoblastoma in at least one eye, deemed
manageable with IAC in one side and without IV chemotherapy:
1. Unilateral Retinoblastoma classified as group B, C (if vitreous seeds < 3 mm), D or E
with no invasion of the anterior segment, and without massive tumor of more than 2/3
of the eye, eligible for conservative management, or
2. Bilateral Retinoblastoma but with very unbalanced lesions between the two eyes: one
eye group D or E without invasion of the anterior segment or massive tumor of more
than 2/3 of the eye, eligible for IAC, and the other eye eligible for local treatment
only (without IAC).
Study 2 inclusion criteria:
8.2. Retinoblastoma eligible for conservative management although not manageable with IAC:
1. Unilateral Retinoblastoma in children below 6 months of age, classified as Group A, B,
C or D, with or without vitreous seeding, compatible with conservative management, or
2. Bilateral Retinoblastoma classified as group A, B, C D, or E without invasion of the
anterior segment, and/or massive tumors of more than 2/3 of the eye and eligible for
conservative management.
Exclusion Criteria:
Overall study non-inclusion criteria:
1. RB not eligible for conservative management :
1. Extra-ocular extension of the disease, or
2. Group E eyes with invasion of the anterior segment, and/or massive tumors of more
than 2/3 of the eye.
2. Patient older than 6 years of age.
3. Patients with another associated disease contra indicating systemic chemotherapy.
4. Previously treated retinoblastoma by chemotherapy.
5. Patients already treated for another malignant disease.
6. Patient with any psychological, familial, sociological or geographical condition
potentially hampering compliance with the study protocol and follow-up schedule.
7. Patients whose parents have not accepted the treatment regimen after explanation of
it.
8. Contraindication to study drug mentioned in SmPC (Summary of Products Characteristics)
of the study drugs.
9. Inclusion in another experimental anti-cancer drug therapy.
Study 1 non-inclusion criteria:
10. Any contraindication or concomitant disease that would preclude the Study 1 treatment
procedure and could delay treatment.
These patients should be eligible for Study 2.
Gender
All
Ages
6 Months - 6 Years
Accepts Healthy Volunteers
No
Contacts
Livia LUMBROSO LE ROUIC, MD, +33(0)144324163, [email protected]
Location Countries
France
Location Countries
France
Administrative Informations
NCT ID
NCT04681417
Organization ID
IC 2019-05
Responsible Party
Sponsor
Study Sponsor
Institut Curie
Collaborators
Fondation Rothschild Paris
Study Sponsor
Livia LUMBROSO LE ROUIC, MD, Principal Investigator, Institut Curie
Verification Date
November 2022